Costs and efficacy of "on demand" low-dose immunoprophylaxis in HBV transplanted patients: Experience in the Romanian program of liver transplantation

Journal of Gastrointestinal and Liver Diseases

Volumn 17, Issue 4, 2008, Pages 383-388

  Iacob, Speranta ^a   Hrehoreţ, Doina ^a   Matei, Emil ^a   Dorobanţu, Bogdan ^a   Gangone, Eliza ^a   Gheorghe, Liana ^a   Popescu, Irinel ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

Cost efficacy; Hepatitis B virus; Immunoprophylaxis; Liver transplantation

Indexed keywords

HEPATITIS B ANTIBODY; IVHEBEX; LAMIVUDINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DELTA AGENT HEPATITIS; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; RECURRENT INFECTION; SURGICAL MORTALITY; SURVIVAL RATE;

ADULT; COMORBIDITY; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS D; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LAMIVUDINE; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGRAM EVALUATION; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; ROMANIA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67149139593     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Berenguer M, Wright TL. Treatment of recurrence of hepatitis B in transplant patients. J Hepatol 2003; 39: S190-S193.
2. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-1427.
3. Alter M. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39: S64-S69.
4. Gheorghe L, Popescu I, Iacob R, Iacob S, Gheorghe C. Predictors of death on the waiting list for liver transplantation characterized by a long waiting time. Transpl Int 2005; 18: 572-576.
5. www.optn.org. Accessed 6-Apr-2008
6. Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol 2006; 101: 1370-1378.
7. Roche B, Samuel D. Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results. J Hepatol 2003; 39: S181-S189.
8. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-1333.
9. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-1364.
10. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
11. Broelsch CE, Frilling A, Malago M. Should we expand the criteria for liver transplantation for hepatocellular carcinoma - Yes, of course! J Hepatol 2005; 43: 569-573.
12. Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology 2001; 120: 749-762.
13. Mayo Clinic. Nationwide Decrease in the Need for Liver Transplant. Press release 31-Oct-2007. www.newswise.com. Accessed 6-Apr-2008
14. Kim WR, Benson J, Hindman A, Brosgart C, Fortner-Burton C. Decline in the need for liver transplantation for end stage liver disease secondary to hepatitis B in the US. Hepatology 2007; 46: 57A.
15. Bianchi P, Porro CB, Coltorti M, et al. Occurrence of Australia antigen in chronic hepatitis in Italy. Gastroenterology 1972; 63: 482-485.
16. Rosina F, Conoscitore P, Cuppone R, et al. Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 1999; 388 Iacob et al 117: 161-166.
17. Gheorghe L, Iacob S, Simionov I, et al. Natural history of compensated viral B and D cirrhosis. Rom J Gastroenterol 2005; 14: 329-335.
18. Onaca NN, Levy MF, Sanchez EQ, et al. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. Liver Transpl 2003; 9: 117-123.
19. Iacob S, Cicinnati VR, Hilgard P, et al. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation 2007; 84: 56-63.
20. Adler M, De Gendt E, Vereerstraeten P, et al. Value of the MELD score for the assessment of pre- and post-liver transplantation survival. Transplant Proc 2005; 37: 2863-2864.
21. Jacob M, Copley LP, Lewsey JD, et al. Pretransplant MELD score and post liver transplantation survival in the UK and Ireland. Liver Transpl 2004; 10: 903-907.
22. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104-111.
23. Ottobrelli A, Marzano A, Smedile A, et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991; 101: 1649-1655.
24. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
25. Caccamo L, Agnelli F, Reggiani P, et al. Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection. Transplantation 2007; 83: 1341-1344.
26. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-1535.
27. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402-409.
28. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007; 14 (Suppl 1): 37-44.
29. Gish RG, McCashland T. Hepatitis B in liver transplant recipients. Liver Transpl 2006; 12 (11 Suppl 2): S54-64.
30. Dan YY, Wai CT, Yeoh KG, Lim SG. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl 2006; 12: 736-746.
31. Jiao ZY, Jiao Z. Prophylaxis of recurrent hepatitis b in Chinese patients after liver transplantation using lamivudine combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen. Transplant Proc 2007; 39: 1533-1536.
32. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004; 77: 1203-1208.
33. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.